Global Peptide Drug Conjugate Market & Clinical Trials Insight 2026 Report Highlights:
First FDA Approved Peptide Drug Conjugate: Pepaxto (Melphalan Flufenamide)
Pepaxto Clinical & Commercial Insight: Dosage, Patent, Price, Sales Forecast
Peptide Drug Conjugate Sales Opportunity: US, Europe, Japan & South Korea
Global Peptide Drug Conjugate Clinical Pipeline: > 20 Drugs
Clinical Trials Insight by Company, Country, Indication
Patent Insight of Peptide Drug Conjugates
Profile & Clinical Pipeline Insight of Companies Developing Peptide Drug Conjugates
Download Report:
Over the last few years, there has been rapid research for the development of novel cancer therapies which have the ability to specifically target the cancer cells. The widespread efforts by researchers have enabled them to utilize the therapeutic potential of peptides in the management of cancer. Till now, several peptide based drugs have entered the market and have shown immense response in the treatment of cancer. Recently, researchers have introduced a new class of peptide drug conjugates, which are formed through the covalent attachment of peptide sequence to a drug via a cleavable linker.